With its initial development started in 2001, by December 2006, marketing authorization was gained by KFDA and was launched in the market by end of 2007. Although the market size of CLOTINAB is small, it serves a great significance as the first Korean therapeutic antibody that is competitive against the global companies in the fast growing therapeutic antibody market.
Overview and Features
CLOTINAB(Abciximab) is a monoclonal antibody that binds to the GPllb/llla of the glycoprotein of the human platelet. It inhibits the final common pathway of platelet agglutination and acts entirely different to the conventional mechanism showing more substantial anti-thrombotic effect.
-
Ingredient(API): Abciximab 2.0mg/1ml in 10mg/5ml vial
-
Appearance: colorless liquid in colorless vial
-
Indication: Supplement to Heparin and Aspirin to prevent ischemic myocardial complications during Percutaneous Coronary Intervention procedure to the high risk patients
-
Dosage and Usage: Recommended dosage 60-10 minutes prior to PCI procedure to administer intravenously 0.25mg/kg in bolus and continuous infusion of 0.125ug/kg/min(max. 10ug/min) in the next 12 hours.
-
NHI Code: 668500020
